Relay Therapeutics Price Target Raised to $17.00

Wells Fargo boosts price target on biotech company's stock

Mar. 20, 2026 at 5:56am

Got story updates? Submit your updates here. ›

Relay Therapeutics (NASDAQ:RLAY) had its price target increased from $15.00 to $17.00 by Wells Fargo & Company, who maintained an "overweight" rating on the stock. The biotech company's stock has received a range of ratings from analysts, with one "sell" rating, five "buy" ratings, and an average target price of $17.17.

Why it matters

Relay Therapeutics is a clinical-stage biotech company focused on developing precision therapies for oncology. The increased price target from Wells Fargo suggests the investment firm sees potential upside in the company's stock, which could signal optimism about the progress of Relay's drug development pipeline.

The details

In a research report, Wells Fargo raised its price target on Relay Therapeutics from $15.00 to $17.00 while maintaining an "overweight" rating on the stock. Other analysts have also weighed in, with Guggenheim increasing its price target from $15.00 to $22.00 and issuing a "buy" rating, while Weiss Ratings reiterated a "sell (d-)" rating.

  • The research report from Wells Fargo was released on Tuesday morning.

The players

Relay Therapeutics

A clinical-stage biotechnology company focused on developing precision therapies for oncology, headquartered in Cambridge, Massachusetts.

Wells Fargo & Company

A major American multinational financial services company that provides various banking, investment, and mortgage products and services.

Guggenheim

An investment management firm that provides financial services, including investment banking advisory, asset management, capital markets services, and investment research.

Weiss Ratings

An independent rating agency that provides financial strength ratings and analysis on banks, credit unions, insurance companies, and other financial institutions.

Got photos? Submit your photos here. ›

The takeaway

The increased price target from Wells Fargo suggests Wall Street sees potential upside in Relay Therapeutics' stock, which could indicate optimism about the progress of the company's oncology drug development pipeline. However, the mixed analyst ratings highlight the uncertainty and differing views around the biotech firm's prospects.